Photocure ASA · OSL:PHO
Photocure ASA — Investor Presentation (July 2025)
16 slides from Photocure ASA's investor presentation, July 2025
Slide 1: Photocure ASA Corporate Presentation
Photocure ASA Corporate Presentation July 2025 – For Investors
Slide 2: Disclaimer
Disclaimer By reading this company presentation (the “Presentation”) or attending any meeting or oral presentation held in relation thereto, you (the “Recipient”) agree to be bound by the following terms, conditions and limitations. The Presentation has been produced by Photocure ASA (the “Company”)
Slide 3: Global commercial-stage bladder cancer company
Global commercial-stage bladder cancer company Direct sales in U.S. & ~100 Europe employees Commercial: with worldwide 35 - North Am. partnerships 27 - Europe 2024 revenue Our precision diagnostic is NOK 525M approved for use in (USD 47M) Gross margin ~30 Symbol: PHO (OSE) Public company traded on t
Slide 4: Leading change in Bladder Cancer: Investment Highlights
Leading change in Bladder Cancer Investment Highlights Established position as an innovation leader in the large / underserved bladder cancer treatment market Hexvix/Cysview: the foundation in precision diagnostics for bladder cancer care ($1.9B TAM) Strong clinical evidence, treatment guidelines &
Slide 5: Bladder cancer has been chronically underserved
Bladder cancer has been chronically underserved COMMON (8th most common cancer worldwide1a) EXPENSIVE Highest 614K 220K per-patient USD >5.7B 6.5B lifetime new cases deaths annually treatment annually1b of which 75% costs of any Cost of Cost of Bladder Bladder Cancer Cancer in in are men1b the U.S.,
Slide 6: Hexvix/Cysview and Blue Light Cystoscopy (BLC): a Drug Device combination
Hexvix®/Cysview® and Blue Light Cystoscopy (BLC ®): a Drug Device combination Blue Light Cystoscopy (BLC®) The drug preferentially accumulates Hexvix / Cysview is used with a in bladder cancer cells blue light enabled cystoscope making them glow bright pink supplied by Karl Storz, Richard under blue
Slide 7: BLC creates a standard of care for cancer detection and management
BLC creates a standard of care for cancer detection and management Bladder cancer seen under blue light during BLC, Courtesy of Professor Dirk Zaak; Traunstein, Germany. Quoted from scientific literature and approved prescribing information*: Improved detection vs. white light cystoscopy alone1–4 He
Slide 8: High need to use enhanced visualization like BLC for better outcomes
High need to use enhanced visualization like BLC for more complete resection, better staging and grading leading to better outcomes Our Focus Average WW Price Per TURBT or Surveillance Cystoscopy Procedure = ~US$800.00 Urologist TURBT performs initial procedure, cystoscopy biopsy to confirm Blood in
Slide 9: Weight of clinical evidence clearly favors BLC
Weight of clinical evidence clearly favors BLC Blue Light Cystoscopy White Light Cystoscopy / with Hexvix®/Cysview® Other Visual Enhancement WLC misses lesions only detected with BLC Randomized-Control Clinical Trial Data 9 Photocure RCTs / ~2,200 NMIBC patients Limited RCTs for visual enhancement t
Slide 10: Supportive environment for BLC as the standard of care
Supportive environment for BLC as the standard of care to detect and manage bladder cancer Global and national guidelines recommend Hexvix®/Cysview® Photocure Corporate Presentation © Photocure - Confidential 10
Slide 11: Hexvix/Cysview key market enablers support our ambition to become standard of care
Hexvix®/Cysview® – key market enablers support our ambition to become standard of care Key success factors TAM** ~US$1.9B¹ 100% Approval Surgical & surveillance 75% Acceptance Major & local guidelines* 50% Permanent and favorable Access reimbursement DACH 25% NORDIC “Activated” Patient demand via ad
Slide 12: Our Mission: Delivering transformative solutions to improve the lives of bladder cancer patients
Our Mission: Delivering transformative solutions to improve the lives of bladder cancer patients Photocure’s growth strategy 03 Leverage 01 02 Partner, in-license, acquire synergistic assets to Expand expand product portfolio Accelerate Generate sales in new Drive the breadth geographies and depth o
Slide 13: Strategic Priorities & Initiatives
Strategic Priorities & Initiatives Continue to grow Develop BLC’s role as a Expand product portfolio / Hexvix®/Cysview® sales and definitive diagnostic in bladder Diversify global product offering in increase Company profitability cancer care / Improve access bladder cancer / uro-oncology Provide an
Slide 14: Value-generating Asieris Programs
Value-generating Asieris Programs: Cevira: Out-licensed worldwide rights to Asieris for development/commercialization Past Progress Recent News & Expectations Potential for Photocure 1st Non-Invasive Regulatory review and Candidate for commercialization in Cervical HSIL; Phase III Trial China Regula
Slide 15: Catalysts to Drive Growth Acceleration
Catalysts to Drive Growth Acceleration Expand BLC usage in North America with new tower installations, upgrades to high-definition equipment, adoption of ForTec mobile tower solution in the U.S. Drive European growth in our Established and Priority Growth Markets, facilitate launch of Olympus’ new b
Slide 16: Leading change in Bladder Cancer: Investment Highlights
Leading change in Bladder Cancer Investment Highlights Established position as an innovation leader in the large / underserved bladder cancer treatment market Hexvix/Cysview: the foundation in precision diagnostics for bladder cancer care ($1.9B TAM) Strong clinical evidence, treatment guidelines &